Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P01185 (vasopressin)
 23,126 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An account is given of experience acquired with the prolonged administration of a new vasopressin analogue, 1-deamino-8-D-arginine vasopressin (DDAVP), to patients with diabetes insipidus. The antidiuretic effect of this compound was compared with that of the long-acting Pitressin Tannate, containing a pituitary extract. It was found that DDAVP induces a far more significant antidiuretic effect than does Pitressin Tannate. Its application is not accompanied by any side effects, nor is its effectiveness decreassed after repeated administration. Similar conclusions were reached with the outpatient treatment of diabetes insipidus patients. The results indicate that nasally-administered Adiuretein-SD can be well utilized in the prolonged treatment of diabetes insipidus.
 ...
PMID:Comparative study of the antidiuretic effects of Adiuretin-SD (DDAVP) and Pitressin Tannate in diabetes insipidus. 63 64

The plasma vasopressin response to acute water ingestion was evaluated in 20 patients with myxedema prior to definitive treatment and in eight of these same patients following therapy of their hypothyroidism. Vasopressin levels were elevated and failed to completely suppress following water ingestion in 15 subjects (75 per cent). Two hypothyroid patients with elevated plasma vasopressin levels (10 per cent) had a normal renal response to the water challenge suggesting partial end organ hormonal unresponsiveness. In three (15 per cent) of the five patients with suppressible vasopressin, water excretion was impaired indicating a nonvasopressin-mediated renal defect. In eight patients restudied after achievement of a euthyroid state, vasopressin inhibition and urinary excretion were normal following the oral water load. Although intrinsic renal changes in the hypothyroid state may contribute to the observed defect in water diuresis, the present study suggests a role of endogenous vasopressin in this disorder.
 ...
PMID:The role of vasopressin in the impaired water excretion of myxedema. 64 27

The hepatic arterial and hepatic portal venous vascular beds of the chloralose-urethane anesthetized dog were perfused simultaneously in situ. Vasopressin (10 mU = 1 unit) was injected in graded increasing doses into the hepatic artery and into the portal vein. Both intra-arterial and intraportal vasopressin elicited both hepatic arterial vasoconstriction and hepatic venous dilation; the delay in onset of both hepatic vascular effects was significantly shorter than that for any succeeding systemic effects (a rise in systemic arterial pressure and fall in heart rate), showing that they were not attributable to recirculation or to arterial baroreceptor reflexes. Injections of vasopressin into the inferior vena cava at the level of the hepatic veins consistently produced smaller hepatic vascular effects than either intra-arterial or intraportal injections of the same doses. The results are discussed in the context of the therapeutic role of vasopressin in controlling gastrointestinal bleeding and portal hypertension.
 ...
PMID:The effects of intra-arterial and intraportal injections of vasopressin on the simultaneously perfused hepatic arterial and portal venous vascular beds of the dog. 68 53

Vasopressin and oxytocin pathways were specifically localized in glutaraldehyde-paraformaldehyde fixed rat brains, with the use of the unlabelled antibody enzyme method and purification of the first antiserum. Vasopressin and oxytocin containing pathways were traced from the paraventricular nucleus towards the dorsal and ventral hippocampus, the nuclei of the amygdala, substantia nigra and substantia grisea, nucleus tractus solitarius, nucleus ambiguus and to the substantia gelatinosa of the spinal cord. In addition, a vasopressin containing pathway between the suprachiasmatic nucleus and the lateral habenular nucleus was demonstrated. The possible nature (axons or dendrites) and role of these extrahypothalamic fibres is discussed in relation to water balance, milk ejection and avoidance behaviour.
 ...
PMID:Intra- and extrahypothalamic vasopressin and oxytocin pathways in the rat. Pathways to the limbic system, medulla oblongata and spinal cord. 69 26

This work proposes the use of (a) a commercially available homologous system AVP antibody-AVP (Arginine Vasopressin) standard and (b) new acquisitions for the improvement of sensitivity for AVP radioimmunoassay by separate or simultaneous use of two-phase sequential incubation and epsilon-aminocaproic acid (EACA). The antiserum used in the system described is very specific since none even cross-reacted with lysine vasopressin (LVP) and has an apparent affinity constant (K) of 0.909 +/- 0.047 X 10(12) l/mol. This is sufficiently high to detect 0.5 +/- 0.2 pg/tube, which is theoretically expected of biological AVP. The total assay time is less than 48 h.
 ...
PMID:A practical proposal for arginine-vasopressin radioimmunoassay. 69 31

In order to test the integrity of central receptors, spontaneously hypertensive rats (SHR) of the Okamoto strain and weight-matched control rats of the Wistar Kyoto (WKY) strain were given intracerebroventricular (i.vt.) injections of carbachol and norepinephrine. The rats, in an unanesthetized, unrestrained state, were tested for drinking, antidiuretic and pressor responses. Antidiuretic hormone release was determined by using water loaded, diuresing rats as their own antidiuretic hormone bioassay. Blood pressure was measured directly from a femoral artery catheter. Drinking responses to i.vt. carbachol and antidiuretic responses to i.vt. carbachol and norepinephrine infusions were not different between SHR and WKY while pressor responses were potentiated in SHR. The potentiated pressor responses to central carbachol and norepinephrine injections were the result of increased vascular responsiveness to the antidiuretic hormone released by these drugs. A second, neurally mediated, factor was also apparent to i.vt. carbachol injections. This additional factor could be increased sympathetic outflow to central drug stimulation, increased vascular reactivity to sympathetic outflow, decreased baroreflex responses or a combination of the above.
 ...
PMID:Central cholinergic and noradrenergic stimulation in spontaneously hypertensive rats. 70 27

Vasopressin, or vasopressin antiserum, was injected into a lateral cerebral ventricle of conscious rats. These rats were normally hydrated, cellular dehydrated (NaCl loading) or hypovolemic (polyethylene glycol model). Elevation or reduction of vasopressin in cerebrospinal fluid produced no consistent change in consummatory behavior, urine volume or sodium and potassium excretion. These results show vasopressin in cerebrospinal fluid not to be an absolute requirement for maintenance of hydration or for response to acute volume and osmotic stimuli.
 ...
PMID:Consummatory behavior and urine production after cerebroventricular injection of vasopressin and vasopressin antiserum. 71 May 11

Previous studies have shown that decreasing blood flow in the superior mesenteric artery (SMA) by the infusion of intra-arterial vasopressin into or partial mechanical obstruction of the SMA by a balloon catheter (partial balloon obstruction) causes similar alterations in splanchnic hemodynamics, but divergent changes in systemic hemodynamics. The effects of these two methods of reducing SMA blood flow were compared in each of six anesthetized normal dogs. Vasopressin and partial balloon obstruction induce similar reductions in portal pressure (-54 +/- 12% vs. -46 +/- 11%), wedge hepatic vein pressure (-54 +/- 13% vs. -53 +/- 18%), and portal venous flow (-34 +/- 7% vs. -37 +/- 7%). Significantly different effects between intra-arterial vasopressin and partial balloon obstruction were observed, however, in cardiac output (a decrease of -24 +/- 5% vs. an increase of +12 +/- 4%) (P less than 0.001), heart rate (-8 +/- 3% vs. 0) (P less than 0.05), and systemic vascular resistance (+36 +/- 8% vs. -2 +/- 2%) (P less than 0.005), respectively. These results indicate that the two procedures are equally effective in reducing portal venous pressure and blood flow. Partial balloon obstruction, however, does not induce the potentially deleterious systemic hemodynamic effects seen with vasopressin infusion. In fact, some of the changes observed with partial balloon obstruction, especially the increase in cardiac output, are considered to be beneficial. In an additional five dogs, partial balloon obstruction was maintained for 5 hours. Throughout, the reduction in portal venous pressure (hepatic venous wedge minus hepatic venous free pressure) was maintained at less than half of the baseline levels (4.75 +/- 0.43 vs. 2.25 +/- 0.32 mm Hg), and the mean arterial pressure at baseline values. All of the dogs survived and were well at 1 week after the prolonged partial obstruction. No abnormalities were observed in the anatomical or histological studies of the small intestine. This study suggests that partial balloon obstruction of the SMA has theoretical therapeutic advantages over intra-arterial vasopressin for reducing portal venous pressure.
 ...
PMID:Pharmacological vs. mechanical reduction in portal pressure: a comparative study. 71 83

It was established in experiments on adult (8--12 month) and old (26--32 month) rats that in ageing the sensitivity of the cardiovascular system to certain hormones--adrenaline, vasopressin, insulin, thyroxine, estradiol dipropionate--grows while its reactivity to them diminishes. The administration of these hormones causes significant changes in hemodynamics and myocardial contractility. Adrenaline and thyroxine lead to an increase in the blood minute and stroke volume, arterial pressure, cardiac index and left ventricular work index, maximum rate of intraventricular pressure growth, maximum rate of myocardial fiber shortening, and in the contrastility index. Vasopressin and insulin cause a decrease in the indices of general hemodynamics. The increased sensitivity of the heart to hormones at old age and diminution of its reactivity lead to prolonged, protracted reactions of the cardiovascular system in elderly and old individuals.
 ...
PMID:[Hormonal regulation of the heart in aging]. 73 78

Effects of pentagastrin (1-4096 ng/kg), cholecystokinin (1-4096 mU/kg, CCK) and vasopressin (.032-128 mU/kg) on gastrointestinal motility and blood flow, were determined by simultaneous measurement of blood flow (electromagnetic flow probes) to and motor activity (strain gages) of corpus, antrum, duodenum, jejunum, and colon of anesthetized dogs. Antral contractile amplitude was increased by pentagastrin at relatively low doses. Pentagastrin also increased corpus blood flow, corpus tone and antral blood flow. Gastric contractile frequency was least sensitive to pentagastrin. Corpus blood flow was decreased and small intestinal blood flow was increased by cholecystokinin at relatively low doses. CCK also increased small intestinal contractile amplitude and, at higher doses, antral contractile amplitude, and duodenal tone. Time-effect relation and sensitivity were different for the hemodynamic and motor responses to pentagastrin and to cholecystokinin. This shows the lack of correlation between vasoactive and motor-stimulating properties of these drugs. However, strong drug-induced contractions were shown to impede antral blood flow (pentagastrin and CCK) by about 35% and duodenal and jejunal blood flow (CCK) by resp. 70 and 60%. Vasopressin reduced blood flow to stomach and intestines by 50-80%, without affecting gastrointestinal motility.
 ...
PMID:Motility and hemodynamics of the canine gastrointestinal tract. Stimulation by pentagastrin, cholecystokinin and vasopressin. 74 69


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>